Genfit (NASDAQ:GNFT) Stock Price Up 1.2%

Shares of Genfit S.A. (NASDAQ:GNFT - Get Free Report) were up 1.2% during mid-day trading on Friday . The stock traded as high as $3.49 and last traded at $3.49. Approximately 1,426 shares changed hands during trading, a decline of 90% from the average daily volume of 14,712 shares. The stock had previously closed at $3.45.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Genfit in a research note on Friday, April 5th.

Genfit Stock Up 1.2 %

The firm has a 50 day moving average price of $3.57 and a two-hundred day moving average price of $3.53. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.94 and a current ratio of 2.94.

Institutional Investors Weigh In On Genfit

A hedge fund recently raised its stake in Genfit stock. Optiver Holding B.V. grew its holdings in Genfit S.A. (NASDAQ:GNFT - Free Report) by 2,229.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,359 shares of the company's stock after purchasing an additional 78,823 shares during the period. Optiver Holding B.V. owned approximately 0.17% of Genfit worth $315,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.24% of the company's stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.